To determine whether isotype matched immunoglobulin (Ig; Ig 0 k/Ig 0 l) ratios had prognostic significance in patients with intact Ig multiple myeloma (MM). Novel immunoassays measuring serum concentrations of the Ig heavy chain/light chain (HLC) subsets IgGk, IgGl, IgAk and IgAl were compared with monoclonal protein ('M-spike') quantification by serum protein electrophoresis, b 2 -microglobulin (b 2 -M), albumin, serum free light chain (FLC) and cytogenetic markers in relation to outcome in 339 MM patients. Abnormal IgGk/IgGl and IgAk/IgAl ratios present in the respective tumor isotypes at clinical presentation were predictive of shorter progression-free survival (PFS) (hazard ratio (HR) 1.9; P ¼ 0.0002), predominantly due to the suppression of the uninvolved (polyclonal) Ig of the same isotype as the tumor (HR 1.8; P ¼ 0.002). No significant associations were observed between PFS and M-spike concentrations, suppression of non-tumor Igs of different isotypes or FLC k/l ratios. b 2 -M and HLC ratios were independently prognostic (P ¼ 0.045 and P ¼ 0.001). A staging system using b 2 -M and extreme HLC ratios (o0.01 or 4200) had greater prognostic value than the widely used ISS staging system (HR 1.7; P ¼ 0.00002 vs HR 1.3; P ¼ 0.017). These results suggest that HLC ratios may have a role in clinical management of MM.
INTRODUCTION
International guidelines recommend serum protein electrophoresis and serum free light chain (FLC) immunoassays with derived kappa/lambda (k/l) ratios to screening for monoclonal gammopathies. 1, 2 Compared with the absolute FLC concentration, the use of the k/l ratio is a more sensitive marker of monoclonal FLC production as it incorporates suppression of the non-tumor (uninvolved) FLC in its calculation. 3 In addition, baseline FLC k/l ratios have been reported to be prognostic in multiple myeloma (MM), 4, 5 in contrast to densitometric measurements of intact immunoglobulin (Ig) M-spike. 6, 7 The added utility of FLC k/l ratios has prompted interest in the analysis of k/l ratios of intact Igs, now possible due to the availability of immunoassays for the intact Ig subsets; IgGk, IgGl, IgAk and IgAl (heavy chain/ light chain (HLC) immunoassays). 8, 9 These molecules are then measured in pairs to produce ratios of tumor-produced (involved) Ig to polyclonal (uninvolved) Ig concentrations, for example, IgGk/ IgGl. Preliminary evaluations suggest that HLC k/l ratios are diagnostically sensitive in MM and AL (amyloid light chain) amyloidosis, can be used to monitor both diseases 10, 11 and in some instances may be the only useful marker of disease progression. 12 One report also proposes HLC ratios may be prognostic in monoclonal gammopathies of undetermined significance. 13 Of particular interest is the ability of the HLC assays to quantify suppression of the uninvolved, polyclonal Igs of the same isotype as the tumor. To date, this has not been possible, either by immunoassays or by electrophoretic methods.
The purpose of the current study was to determine whether HLC measurements, including Ig isotype-specific suppression, had prognostic significance in patients with intact Ig MM. The relationship between HLC measurements and other prognostic indicators such as M-spike, b 2 -microglobulin (b 2 -M), albumin, FLCs and cytogenetic abnormalities was also examined.
PATIENTS AND METHODS

Patients and serum samples
Presentation serum samples from patients recruited to the Inter Groupe Franc¸ais du Myelome 2005-01MM trial were studied, excluding those with FLC-only disease. A total of 339 patients were evaluated, comprising 245 IgG (166 IgGk, 79 IgGl) and 94 IgA (60 IgAk, 34 IgAl) isotypes. All samples were taken at the time of initial clinical presentation and patients were monitored for progression-free survival (PFS) and overall survival (OS). In accordance with the trial protocol, patients received bortezomib (Velcade, Millennium Pharmaceuticals, Cambridge, MA, USA) and dexamethasone or VAD (vincristine, doxorubicin and dexamethasone) as induction therapy plus or minus DCEP (dexamethasone, cyclophosphamide, etoposide and cisplatin), followed by high-dose melphalan with a stem cell autograft as first line therapy.
14 Serum samples were stored at À 80 1C until analysis; insufficient samples were available for some measurements ( 16 ), M-spike by serum protein electrophoresis densitometry (Sebia, Paris, France) and the cytogenetic markers Del:13, t4:14 and Del:17p by fluorescence in situ hybridization. 17 
Statistical analysis
Associations between different assay methods and different markers were tested using Pearson's correlation analysis. Differences in PFS and OS between patient groups were investigated using Kaplan-Meier survival curves with the Mantel-Cox/log rank test used to indicate significance. A Cox proportional hazards model was utilized to compare the association of all variables with PFS. All statistical analyses were performed using SPSS version 18 (Chicago, IL, USA).
Ethics permission
The study was approved by the relevant national health authority agency and the Ethics Committee of the University of Nantes.
RESULTS
The serum concentrations of IgG and IgA HLC in IgG and IgA MM patients were determined, along with serum FLCs (Table 1) Figures 1a and b summarize IgG or IgA HLC measurements for all patients and normal samples using HLC Ig 0 k/Ig 0 l dot plots. All IgG MM patients had IgG HLC ratios outside the 95% confidence limits of the normal ranges; the same was true for IgA MM HLC ratios.
During the study period, 125 patients (37%) had disease progression and 46 patients (14%) died. When patients were Figure 2b were 103 000 and 8500 mg/l, respectively.
Prognostic value of Ig 0 k/Ig 0 l ratios and Ig 0 -isotype-matched suppression A Bradwell et al categorized according to baseline M-spike concentrations above or below the median values, no significant differences in PFS (P ¼ 0.14) or OS (P ¼ 0.46) were observed. Similarly, there was no significant difference in outcome when patients were categorized into tertiles of M-spike concentration (PFS: P ¼ 0.07 and OS: P ¼ 0.4). Nephelometric measurements of total IgG or IgA also failed to demonstrate significant association with outcome. In contrast, there was a significant correlation between HLC k/l ratios and outcome. Figure 2a compares the PFS for patients with HLC ratios above or below median concentrations (using k/l ratios for IgGk and IgAk tumors and l/k ratios for IgGl and IgAl tumors). The difference in PFS between the two arms (HLC ratio 4 or omedian) was statistically significant (P ¼ 0.022). This significance increased when more extreme ratios were considered (40.01 to o200 compared with o0.01 or 4200). Using this stratification, B1/3rd of the patients (n ¼ 116) had more extreme HLC ratios associated with shorter PFS (hazard ratio (HR) 1.9; P ¼ 0.0002: Figure 2b ). Using the same HLC ratio stratification for OS, there was a tendency towards significant difference between the two groups (P ¼ 0.08), although there were only 14% deaths at this stage of the trial.
When IgG and IgA MM patients were analyzed separately, increasingly abnormal HLC k/l ratios were associated with shortened PFS in IgG patients (Figure 2c , Po0.001) but not in IgA patients (P ¼ 0.32). For IgG patients, the risk of progression rapidly increased with the extent of the ratio abnormality (Figure 2c ), thereby providing support for risk stratification using these more extreme ratios.
The contribution of involved and uninvolved HLC to the risk of progression was examined. Figure 3a shows PFS for involved HLC levels when comparing IgG and IgA patients who had concentrations in the top tertile with the rest (HR 1.4; P ¼ 0.039). However, the association between suppressed levels of the uninvolved HLC was more significantly associated with adverse PFS (Figure 3b ; HR 1.8; P ¼ 0.002). Thus, suppression of the uninvolved HLC concentrations accounted for the majority of the association between HLC k/l ratios and PFS.
No significant association was observed between PFS and concentrations of the non-tumor isotype above or below median values in IgA patients, IgG and IgM correlations with PFS were not significant (P ¼ 0.169 and P ¼ 0.477), and in IgG patients, IgA and IgM correlations were not significant (P ¼ 0.952 and P ¼ 0.977). Table 2 shows the correlations between PFS and the various measured parameters using univariate and multivariate Cox regression analysis. HLC k/l ratios and b 2 -M were individually more significant than other markers, including albumin, FLC k/l ratios and cytogenetic tests (Del:13, t4-14 and Del:17p). Multivariate analysis identified HLC k/l ratios and b 2 -M as being significantly correlated with outcome; albumin, FLC ratios and cytogenetic tests made no contribution. Figure 4a shows the correlation between PFS and the ISS stages for all patients (P ¼ 0.017). Figure 4b shows results of a staging system based upon three categories using b 2 -M and HLC ratios: 
DISCUSSION
Here, for the first time we show a correlation between HLC ratio measurements and PFS in MM at diagnosis. In common with previous reports there was no association between baseline M-spike 16 measurements and outcome. Similarly, suppression of the non-tumor associated Ig 0 s were of little prognostic use. The prognostic utility of HLC ratios is largely due to the relative suppression of the polyclonal, uninvolved HLC concentrations. This is the first report of this phenomenon in MM and is supported by similar observations in monoclonal gammopathies of 13 Such HLC isotype-specific suppression of polyclonal Igs suggests that bone marrow microenvironment niches may be affected, selectively, by growth of IgG-or IgA-producing tumor cells.
Prognostic value of Ig
Although uninvolved HLC suppression is the main component of the HLC prognostic utility (HR 1.8; P ¼ 0.002), there is also a weak correlation with the involved HLC concentrations (HR 1.4; P ¼ 0.039), such that a combination (in the form of the HLC k/l ratio) provides the most significantly correlation (HR 1.9; P ¼ 0.0002). Curiously, HLC k/l ratios had a greater prognostic power in IgG MM than in IgA MM. This is likely to be a reflection of the different number of MM patients (245 IgG compared with 94 IgA) analyzed for each isotype. Alternatively, this could be a reflection of a subtle difference between IgA and IgG MM and larger studies are required to investigate these results further.
We propose that the HLC k/l ratio is more prognostic than the serum M-spike level or isotype-specific suppression as the ratio is unaffected by two mechanisms that influence serum measurements of monoclonal Igs. First, variations in hematocrit and plasma volume in MM cause Ig serum concentrations to change by 50% or more, independently of alterations in tumor production rates. 18 As both involved and uninvolved HLC measurements are affected equally, the Ig 0 k/Ig 0 l ratios compensate for these processes, with better reflection of tumor production rates. Second, serum IgG molecules are removed from the circulation by a concentration-dependent process, so that measurements do not reliably relate to tumor production. IgG Fc receptors located on nucleated cells recycle IgG many times, extending the half-life to 21 days at normal serum concentrations. At high IgG concentrations, IgG Fc receptors are saturated, causing the excess IgG to be catabolised; consequently, the overall half-life of IgG lies somewhere between 3 days (for the component that is rapidly catabolised) and 21 days (for the component that is recycled). As the half-lives of polyclonal IgG and monoclonal IgG are affected equally, IgG HLC ratios are unaffected by changes in IgG half-life and may be a more accurate reflection of tumor production than M-spike concentration.
HLC tests measure the tumor-produced Ig more accurately than total Ig measurements, as they use separate immunoassays for Ig 0 k and Ig 0 l molecules. By comparison, total Ig immunoassays for IgG and IgA include all the polyclonal, non-tumor Igs along with the monoclonal component. Furthermore, traditional, M-spike serum protein electrophoresis measurements by densitometry are limited by co-migrating proteins, such as transferrin being included in any measurements, -a particular concern for fast-migrating IgA M-spikes.
In recent years, cytogenetic abnormalities have been identified as important prognostic factors in MM. Three well known variants were measured in this study; partial or complete deletion of chromosome 13 (Del:13); 19 the specific Ig heavy-chain translocation t4:14; 20 and mono-allelic deletions of the p53 locus-17p13. 21 Although all three markers correlated with PFS associations they were of less prognostic significance than HLC ratios ( Table 2) .
The impact of HLC ratios was particularly apparent using multivariate analysis, where HLC ratios and b 2 -M concentrations were the only significant independent variables for identifying patients with reduced PFS. Several previous studies have shown serum polyclonal Freelite immunoassay FLC k/l ratios to be predictive of survival. 4, 5, 22 This was not observed in this cohort presumably as patients with light chain MM were excluded. Previously, the prognostic utility of serum FLC ratios in predicting OS has been described. In this cohort we had insufficient followup data to perform this analysis and recognize this as a study limitation. Other limitations of this study include relatively small patient numbers for IgA MM compared with IgG MM, on which the main correlations were based. As mentioned above, survival data are lacking as the trial is at a relatively early stage of maturity, with only 14% mortality at the time of analysis. Furthermore, additional studies are required to assess the utility of the HLC measurement in patient monitoring and predicting survival after maximal treatment response.
As shown in this study, HLC ratios are predictive of outcome, which may be useful in disease staging at presentation and in assessing the depth of response. These results need confirmation in other plasma cell dyscrasias (including IgM HLC ratios) and, in particular, it would be of interest to investigate monoclonal gammopathy of undetermined significance, smoldering MM, 23 Waldenstrom's macroglobulinemia and B-cell chronic lymphocytic leukemia.
In summary, we have provided evidence that serum ratios of IgGk/IgGl and IgAk/IgAl correlate with disease outcome in MM. In contrast, total IgG and IgA measurements were of little prognostic utility. Furthermore, HLC k/l ratios were the most significant parameter for outcome prediction in a multivariate analysis that included b 2 -M, albumin and cytogenetic abnormalities. Clearly, HLC measurements provide additional information to standard laboratory tests, which may be of considerable importance in MM patient management.
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